Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06463873 · ClinicalTrials.gov registry record
Study of OmniGraft in Simultaneous Pancreas Kidney Recipients
A clinical trial, sponsored by University of Miami.
- Terminated
- Registry status
- 40
- Enrollment target
NCT06463873 is a clinical trial that was terminated before completion, run by University of Miami. The registered enrollment target is 40 participants.
The verdict
NCT06463873 was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- 40 participants
- Enrollment target
Study Summary
The purpose of this research is learn about how OmniGraf works in kidney pancreas transplant patients. Also, to analyze the performance characteristics of OmniGrafTM (TruGraf Gene Expression Profiling (GEP) and T Cell Receptor Alpha Constant (TRAC) dd-cfDNA) in a population of simultaneous kidney pancreas transplants as a part of routine surveillance, as well as a part of the workup for patients clinically suspected to have rejection of the kidney and/or pancreas.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2025-02-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06463873
The ClinicalTrials.gov registry entry for NCT06463873 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06463873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06463873 about?
NCT06463873 is a clinical study titled "Study of OmniGraft in Simultaneous Pancreas Kidney Recipients". The purpose of this research is learn about how OmniGraf works in kidney pancreas transplant patients. Also, to analyze the performance characteristics of OmniGrafTM (TruGraf Gene Expression Profiling (GEP) and T Cell Receptor Alpha Constant (TRAC) dd-cfDNA) in a population of simultaneous kidney pa...
What is the current status of trial NCT06463873?
This trial is currently terminated. The enrollment target is 40 participants. The study started on 2024-07-01. Estimated completion is 2025-02-11.
Who is sponsoring clinical trial NCT06463873?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.